Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Medicinal Chemicals & Botanical Products · market cap $179M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| EscharEx 5% (EX-02 formulation) | Phase 2 | Superficial Basal Cell Carcinoma |
| EscharEx (5% EX-02 formulation) | Phase 2 | Venous Leg Ulcer |
| EscharEx (EX-02 formulation) | Phase 2 | Venous Leg Ulcer |
| DGD | Phase 3 | Burn |
| EscharEx | Phase 2 | Hard to Heal Wounds |
| Gel Vehicle | Phase 3 | Thermal Burns |
| EscharEx (EX-03) | Phase 3 | Venous Leg Ulcer (VLU) |
| NexoBrid | Phase 3 | Thermal Burns |
Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.